

**Author(s):** Rebecca W. Van Dyke, M.D., 2012

**License:** Unless otherwise noted, this material is made available under the terms of the **Creative Commons Attribution – Share Alike 3.0 License**:  
<http://creativecommons.org/licenses/by-sa/3.0/>

**We have reviewed this material** in accordance with U.S. Copyright Law **and have tried to maximize your ability to use, share, and adapt it.** The citation key on the following slide provides information about how you may share and adapt this material.

Copyright holders of content included in this material should contact [open.michigan@umich.edu](mailto:open.michigan@umich.edu) with any questions, corrections, or clarification regarding the use of content.

For more information about **how to cite** these materials visit <http://open.umich.edu/education/about/terms-of-use>.

Any **medical information** in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

**Viewer discretion is advised:** Some medical content is graphic and may not be suitable for all viewers.

# Attribution Key

for more information see: <http://open.umich.edu/wiki/AttributionPolicy>

## Use + Share + Adapt

{ Content the copyright holder, author, or law permits you to use, share and adapt. }



**Public Domain – Government:** Works that are produced by the U.S. Government. (17 USC § 105)



**Public Domain – Expired:** Works that are no longer protected due to an expired copyright term.



**Public Domain – Self Dedicated:** Works that a copyright holder has dedicated to the public domain.



**Creative Commons – Zero Waiver**



**Creative Commons – Attribution License**



**Creative Commons – Attribution Share Alike License**



**Creative Commons – Attribution Noncommercial License**



**Creative Commons – Attribution Noncommercial Share Alike License**



**GNU – Free Documentation License**

## Make Your Own Assessment

{ Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. }



**Public Domain – Ineligible:** Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) \*laws in your jurisdiction may differ

{ Content Open.Michigan has used under a Fair Use determination. }




**Fair Use:** Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) \*laws in your jurisdiction may differ


Our determination **DOES NOT** mean that all uses of this 3rd-party content are Fair Uses and we **DO NOT** guarantee that your use of the content is Fair.

To use this content you should **do your own independent analysis** to determine whether or not your use will be Fair.

# Approach to the Patient with Jaundice (Bilirubin)



Approach to Patient with Increased Alkaline Phosphatase



Modified from: Kelley Textbook of Internal Medicine, 3rd edition, 1997, pp 663.

## Analysis of liver tests in patients:

In the lecture hand-out are the liver tests of 9 patients. Please review and try to analyze these cases on your own. Assess the cases for:

1. Cholestatic versus hepatocellular disease
2. Acute versus chronic disease
3. Estimate of liver function (good/poor)
4. Possible diseases (there could be a number of diagnoses for some of these)

My own conclusions are given after the cases - please don't read that page until you have gone through the exercise yourself. Questions - ask me in class or in the early morning question/problem sessions.

## Addenda to Syllabus Liver Tests

Cases  
Algorithms

A variety of cases are provided in your syllabus to allow practice in analyzing liver tests.

Try to determine:

1. Type of liver disease
2. Level of liver function (good/poor)
3. Whether disease is acute or chronic, if this is possible from the data given here.

Case 1	Laboratory Findings	
Bilirubin	8.5	(0.2-1.2 mg/dl)
Alkaline Phos.	250	(23-100 IU/ml)
AST	1500	(40-70 IU/ml)
ALT	1750	(40-70 IU/ml)
Albumin	4.0	(3.5-4.5 g/dl)
PT	11.0	(10.5-12.0 sec)

Case 2	Laboratory Findings	
Bilirubin	8.5	(0.2-1.2 mg/dl)
Alkaline Phos.	675	(23-100 IU/ml)
AST	180	(40-70 IU/ml)
ALT	250	(40-70 IU/ml)
Albumin	4.0	(3.5-4.5 g/dl)
PT	11.5	(10.5-12.0 sec)

Case 3	Laboratory Findings	
Bilirubin	3.5	(0.2-1.2 mg/dl)
Alkaline Phos.	190	(23-100 IU/ml)
AST	300	(40-70 IU/ml)
ALT	400	(40-70 IU/ml)
Albumin	4.0	(3.5-4.5 g/dl)
PT	12.0	(10.5-12.0 sec)

Case 4	Laboratory Findings	
Bilirubin	0.8	(0.2-1.2 mg/dl)
Alkaline Phos.	90	(23-100 IU/ml)
AST	2500	(40-70 IU/ml)
ALT	50	(40-70 IU/ml)
Albumin	4.0	(3.5-4.5 g/dl)
PT	11.0	(10.5-12.0 sec)

Case 5	Laboratory Findings	
Bilirubin	9.0	(0.2-1.2 mg/dl)
Alkaline Phos.	200	(23-100 IU/ml)
AST	300	(40-70 IU/ml)
ALT	100	(40-70 IU/ml)
Albumin	3.2	(3.5-4.5 g/dl)
PT	14.5	(10.5-12.0 sec)

Case 6	Laboratory Findings	
Bilirubin	9.0	(0.2-1.2 mg/dl)
Alkaline Phos.	200	(23-100 IU/ml)
AST	2500	(40-70 IU/ml)
ALT	3000	(40-70 IU/ml)
Albumin	4.0	(3.5-4.5 g/dl)
PT	14.5	(10.5-12.0 se)

Case 7	Laboratory Findings	
Bilirubin	1.0	(0.2-1.2 mg/dl)
Alkaline Phos.	555	(23-100 IU/ml)
AST	25	(40-70 IU/ml)
ALT	30	(40-70 IU/ml)
Albumin	4.0	(3.5-4.5 g/dl)
PT	11.5	(10.5-12.0 sec)

Case 8	Laboratory Findings	
Bilirubin	3.0	(0.2-1.2 mg/dl)
Alkaline Phos.	120	(23-100 IU/ml)
AST	85	(40-70 IU/ml)
ALT	95	(40-70 IU/ml)
Albumin	2.0	(3.5-4.5 g/dl)
PT	15.5	(10.5-12.0 sec)

Case 9	Laboratory Findings	
Bilirubin	1.0	(0.2-1.2 mg/dl)
Alkaline Phos.	450	(23-100 IU/ml)
AST	72	(40-70 IU/ml)
ALT	73	(40-70 IU/ml)
Albumin	4.5	(3.5-4.5 g/dl)
PT	11.5	(10.5-12.0 sec)

## Liver Test Cases:

- 1 Hepatocellular disease, probably acute; considerable hepatocyte necrosis, good remaining liver function. Diseases would include acute viral hepatitis.
- 2 Cholestatic disease with severe impairment of bilirubin excretion with well preserved other liver functions, probably acute. Examples include complete bile duct obstruction.
- 3 Hepatocellular disease with relatively mild “hepatitis” on a day to day basis. However, elevated bilirubin (although normal PT/albumin) is unexpected for mild liver injury and suggests this could be chronic process that has, over time, destroyed enough liver cells to achieve at least some degree of liver dysfunction (primarily as abnormalities in bilirubin secretion).
- 4 Isolated marked elevation in AST – this is unlikely to be due to liver disease as all other tests, including ALT, are normal. Look for another organ system that is injured, releasing AST. Most likely muscle necrosis.
- 5 Hepatocellular process with only mild ongoing liver cell necrosis. Impaired liver function suggests cirrhosis/decompensation and low albumin helps to confirm chronic nature of liver disease. High AST/ALT ratio suggests alcohol as a cause. This picture would be typical of severe alcoholic hepatitis, usually with cirrhosis.
- 6 Hepatocellular process with marked necrosis of liver cells. Elevated PT but normal albumin suggests acute disease. Increased PT suggests fulminant liver failure. This would be typical of very severe acute viral hepatitis, severe toxicity (due to drugs such as acetaminophen or carbon tetrachloride) or severe ischemic injury to much of the liver.
7. May not be liver disease – look for other causes of alkaline phosphatase elevation as the other liver tests are normal. Otherwise, this represents cholestatic disease that is mild. Good liver function. No evidence of chronicity so you don’t know the duration of the problem.



8 Hepatocellular disease with very poor liver function - liver decompensation. This probably represents decompensated chronic cirrhosis.

9. Cholestatic liver disease. Although the alkaline phosphatase is markedly elevated (and AST/ALT are slightly elevated), the bilirubin is not elevated. This often occurs with:

A. Partial obstruction of the bile ducts as sufficient bile still reaches the intestine to eliminate bilirubin.

B. Complete obstruction of some of the bile ducts in the liver but not of all ducts. The rest of the liver (non-obstructed part) usually has sufficient reserve to fully eliminate the daily load of bilirubin.